Preview Mode Links will not work in preview mode

Aug 29, 2023

Featuring an interview with Dr Jeremy Abramson, including the following topics:

  • Choice of Bruton tyrosine kinase (BTK) inhibitor as first-line therapy for chronic lymphocytic leukemia (CLL) (0:00)
  • Perspectives on the use of chemoimmunotherapy versus BTK inhibitors as front-line treatment for CLL (2:31)
  • Chimeric antigen receptor (CAR) T-cell therapy-associated ICANS (immune effector cell-associated neurotoxicity syndrome) and infectious complications in patients with CLL (6:21)
  • Available data with bispecific antibodies for CLL (9:38)
  • Sequencing CAR T-cell therapy and pirtobrutinib for patients with previously treated CLL (11:09)
  • Integrating bispecific antibodies into community-based practice; strategies for mitigating associated toxicities (14:25)
  • CD20 versus CD19 as a therapeutic target in lymphomas (20:31)
  • First-line treatment selection for patients with mantle cell lymphoma (23:07)
  • Chemotherapy combined with nivolumab or with brentuximab vedotin as initial therapy for Hodgkin lymphoma (30:12)

CME information and select publications